The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

The introduction of AbbVie’s hepatitis C drugs in 2014 forced Gilead’s hand in the fight for market dominance in hepatitis C.

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

A GLP-1/glucagon dual agonist induced significant weight loss and improved multiple cardiometabolic parameters for adults ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Mazur, GM of LillyDirect, breaks down the platform’s new partnership with Walmart and its implications for the pharma ...

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded ...

American Express is an advertising partner of Motley Fool Money. The Motley Fool has positions in and recommends Amazon, Peloton Interactive, and Pfizer. The Motley Fool recommends Coinbase Global and ...

Here’s what else you need to know to get up to speed and on with your day. Border Patrol agents have arrived in Raleigh, ...